Tag: covid-19 annual vaccine strategy

FDA Meeting Today on Strain Selection for Periodic Covid-19 Vaccine

The FDA Vaccines and Related Biological Products Advisory Committee will meet today from 8:30 am-5:00 pm ET to discuss and make recommendations on strain selection for the periodic updated Covid-19 vaccines for the 2023-2024 vaccine campaign.

The discussion topic will be:

“Based on the evidence and other considerations presented, please
discuss selection of a specific XBB lineage (e.g., XBB.1.5 or
XBB.1.16 or XBB.2.3) for inclusion in the 2023-2024 Formula of
COVID-19 vaccines in the U.S.”

The voting question will be:

“For the 2023-2024 Formula of COVID-19 vaccines in the U.S., does the
committee recommend a periodic update of the current vaccine composition to
a monovalent XBB-lineage?”

UPDATE: The committee upvoted the question unanimously. The word “periodic” was removed from the question. A September 2023 time frame was expected for availability of the new vaccine.

FDA Meeting June 15, 2023 on Strain Selection for Periodic Covid-19 Vaccine

The FDA Vaccines and Related Biological Products Advisory Committee will meet June 15, 2023 from 8:30 a.m.-5:00 p.m. ET “to discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign. This discussion will include consideration of the vaccine composition for fall to winter, 2023-2024.”

FDA Update on Covid-19 Annual Vaccine Strategy

On April 18, 2023 the FDA posted an update on the Covid-19 updated bivalent vaccine and the upcoming immunization strategy for this fall. According to the announcement:

“In June, the FDA will hold a meeting of its VRBPAC to discuss the strain composition of the COVID-19 vaccines for fall of 2023. Much like the FDA does yearly with the influenza vaccines, the agency will seek input from the committee on which SARS-CoV-2 variants and lineages are most likely to circulate in the upcoming year. Once the specific strains are selected for the COVID-19 vaccines, the FDA expects manufacturers to make updated formulations of the vaccines for availability this fall.”